Rhegmatogenous detachments increased with age; myopia, trauma, and history of retinopathy were common underlying risk factors for development of rhegmatogenous retinal detachments.
In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.
At ASRS in New York City, New York, David Eichenbaum, MD, presented “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-year Results on the Phase 3 YOSEMITE and RHINE Trials.”
Treatment with faricimab in patients with neovascular AMD achieved improvements in the visual acuity, central subfield thickness, and pigment epithelial detachments.
At ASRS 2022, Raj K. Maturi, MD, presented a talk entitled, “UBX1325, A Novel Senolytic Therapy for Treatment- Experienced Patients With Chronic DME or Wet AMD: 24-Week Results of a Phase 1 Study.”
At ASRS in New York City, New York, Justis Ehlers, MD, presented a talk entitled, “Higher Order OCT Feature Assessments of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity.” Here he discusses the findings.
Topics spanned from faricimab in nAMD and DME; pediatric retinal detachment surgery; and the relationship between outer retinal integrity and subretinal fluid.
Albert J. Augustin, MD, presented a talk entitled, “First Results of the Miniature Telescope in Dry AMD” in Fort Lauderdale, Florida. The Galilean telescope device offers visual improvements for patients with late-stage AMD.
Results from our recent poll regarding ASRS 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in New York, New York.
The 40th annual scientific meeting of the American Society of Retina Specialists will be held July 13-16 at the Jacob K. Javits Convention Center in New York.
Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.
A team of investigators form Johns Hopkins Medicine say they’ve discovered that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision or if they can be safely weaned off the treatments.
The 40th annual Scientific Meeting of the American Society of Retina Specialists is scheduled for July 13-16, 2022, in New York City, New York, United States.
A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.
The 40th annual Scientific Meeting of the American Society of Retina Specialists is scheduled for July 13-16, 2022, in New York.
Justis P. Ehlers, MD, dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.
A poll for retina specialists regarding their attendance at the 2022 American Society of Retina Specialists 40th Annual Scientific Meeting in New York City, New York. This poll is now closed.
David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.
Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.
Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.
The FDA has accepted the supplemental Biologics License Application of aflibercept injection for review in patients with diabetic retinopathy.
Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.
Richard Rosen, MD, shares insights on how imaging can capture hyalocytes and their movement without the use of dyes.
Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.
David Boyer, MD, discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.
A team led by researchers from the University of Geneva has identified a molecular mechanism that causes degeneration of the eye’s photoreceptors, which can lead to blindness.
Dr Sally Tucker of Ora Europe walks through the clinical trial pathway, describing how Ora addresses complexities to make the path as efficient as possible.
The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous anti-VEGF injection option in development for the treatment of wet AMD and DMO.
